Accueil   Agenda - News   Toutes les news MaaT Pharma and Lutech Sign Licensing Agreement

MaaT Pharma and Lutech Sign Licensing Agreement

 

MaaT Pharma and Lutech Sign Licensing Agreement on Microbiome Therapy for Graft-vs-Host Disease

 

MaaT Pharma, a clinical-stage microbiome therapy company, and SATT Lutech, a private technology transfer company holding the exclusive rights to the scientific findings from research groups at Sorbonne University, APHP, CNRS and INSERM, today announced a licensing agreement under which MaaT Pharma will receive world-wide exclusive rights for the therapeutic application of allogeneic Fecal Microbiome Transplants (FMT) to treat acute Graft-vs-Host Disease (GvHD) in patients following stem cell transplantation.

The technology is based on research performed within the Clinical Hematology Department at Saint-Antoine Hospital and Sorbonne University, Paris, France. The license builds the foundation for MaaT Pharma’s MaaT013 program for which the company recently received authorization from the French regulatory authorities to launch a multicenter Phase 2 study in acute GvHD. GvHD is a major complication of allogeneic hematopoietic stem cell transplantation in which the donor’s immune effector cells attack the recipient’s tissue, causing inflammation, severe damage and often death. 




Lire le communiqué de presse

En poursuivant votre navigation sur ce site, vous acceptez l'utilisation de cookies pour vous proposer des services et offres adaptés à vos centres d'intérêt. En savoir plus... Fermer